Skip to main content
OpenTrials
Completed

NCT Number: NCT05847049

Eplerenone, Aflibercept and Topical Nepafenac Serous Foveal Deta Chment in Central Serous Chorioretinopathy

describing the influence of; combined Eplerenone, intravitreal Aflibercept, and topical Nepafenac; on serous foveal detachment in eyes with CSCR

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Central Serous Chorioretinopathy Eye Diseases Retinal Diseases

Age range

16 year–60 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Kasr alainy faculty of medicine

Cairo, 12311, Egypt

About this study

Retrospective Review of records of eyes with Central serous chorioretinopathy (CSCR) that have been treated in the period between 2015 and 2021

After checking inclusion and exclusion criteria; we will enroll all cases that have been treated by the combination of eplerenone, intravitreal aflibercept and topical nepafenac.

Investigators collected and recorded the following data:

  • Age
  • Gender
  • Systemic hypertension (present or not)
  • Smoking (Yes / No)
  • Best corrected visual acuity (BCVA) (baseline, final)
  • Central macular thickness (CMT) (baseline, final)
  • Serous detachment Height (SDH) (baseline, final)
  • Duration of Follow-up ( in months)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • CSCR eyes treated by combination of Eplerenone, Aflibercept and Nepafenac.

Exclusion criteria

  • • CSCR treated by other modalities
  • CSCR treated by just 1 or 2 components of :Eplerenone, Aflibercept and Nepafenac

Treatment and study plan

Eplerenone , Intravitreal Aflibercept and Topical nepafenac therapy

Other

Eplerenone , Intravitreal Aflibercept and Topical nepafenac therapy

Primary outcomes

  1. Change in central macular thickness (CMT ) in microns

    Time frame: (baseline, 6 months)

    reduction in CMT after therapy

  2. Change in serous detachment height (SDH) in microns

    Time frame: (baseline, 6 months)

    reduction in SDH after therapy

Secondary outcomes

  1. Change in BCVA

    Time frame: (baseline, 6 months)

    number of lines of improvement in BCVA after therapy

  2. Duration of Follow-up ( in months)

    Time frame: (baseline, 6 months)

    Duration of Follow-up ( in months)

  3. Complications (Eplerenone, Aflibercept, and nepafenac)

    Time frame: (baseline, 6 months)

    present or absent

Sponsors and collaborators

Lead sponsor

Dar El Oyoun Hospital

Other

Registry information

Official study title

Influence of Combined Eplerenone , Intravitreal Aflibercept and Topical Nepafenac Therapy on Serous Foveal Detachment in Central Serous Chorioretinopathy (CSCR)

Acronym: CSCR

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
May 6, 2023
Registry last updated
May 6, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.